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Abstract 1 
 2 
 3 
 4 
Background  5 
The World Health Organization (WHO), empowered by the unanimous proclamation at the 6 
United Nations High Level meeting on non-communicable diseases (NCDs) in September 2011, set 7 
a number of key targets for all nations to reach by 2025.[1] The overarching goal is to reduce the 8 
risk of premature deaths (defined as the probability of dying between the ages of 30 years and 70 9 
years of age) from NCDs (cardiovascular disease including stroke (CVD), diabetes mellitus (DM), 10 
cancer and chronic respiratory disease) by 25% by the year 2025 (referred to as “25 x 25”). The 11 
Global CVD Taskforce, comprising the World Heart Federation, American Heart Association, 12 
American College of Cardiology Foundation, European Heart Network, and European Society of 13 
Cardiology, and expanded representation from Asia, Africa, and Latin America along with global 14 
CVD experts, disseminates information and approaches to reach the WHO 2025 targets.[2-4] 15 
To achieve the overarching 25 x 25 target, the WHO identified 8 targets in the 16 
prevention, control, and treatment of 6 key risk factors, as well as two health systems targets 17 
related to the use of essential medicines, technologies, and drug therapies to prevent NCDs, 18 
particularly CVDs. [5] Of the 8 targets, 6 directly align with traditional CVD and stroke risk 19 
factors: 3 risk factors (tobacco use, sodium intake, physical inactivity), 2 biological risk factors 20 
(raised blood pressure (BP), DM/obesity) and 1 management target directed at treatment of 21 
individuals at high risk of CVD.  With CVD as the largest single contributor to global mortality, 22 
accounting for nearly half of the 36 million annual NCD deaths, and with a global cost of nearly 23 
US $863 billion, achieving the global target to reduce premature NCD deaths by 25% requires 24 
that CVD and its risk factors be aggressively addressed by WHO Member States, policymakers, 25 
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professional organizations, public health experts, health care providers, and key stakeholders. 1 
[4]  2 
Although the prevalence of many of these risk factors has improved globally over the 3 
past 30 years, with the exception of DM and obesity, trends are not homogenous (Table 1).[6] 4 
Between 1990 and 2013, the age-standardized CVD death rate decreased by more than 22% 5 
for both ischemic heart disease and stroke.[7] Taking these trends into account, continued 6 
progress towards improving CV health and reducing CVD and stroke deaths is vital to reaching 7 
the overall premature NCD mortality goal by 2025, just one decade away.  The aim of this paper 8 
is to investigate the potential impact of reaching selected targets in the WHO Global Monitoring 9 
Framework on the reduction of premature CVD mortality by 2025 and examine the policy 10 
implications of these predictions. 11 
 12 
Data & Methods  13 
The writing committee reflects the members of the Global CVD Taskforce.  The committee 14 
engaged researchers at the Institute for Health Metrics and Evaluation (IHME), University of 15 
Washington, Seattle, WA, to develop region-specific estimates of premature cardiovascular 16 
mortality in 2025 based on various scenarios. IHME is the coordinating center for the Global Burden 17 
of Disease Study (GBD), a multinational effort to produce consistent estimates of death and 18 
disability by age, sex, and over time for all countries.[7] 19 
 The methods and results of this exercise have been reported in detail.[8] Data were 20 
drawn from the GBD 2013 study.[7] All estimates were produced separately for each age-sex-21 
country-disease specific strata and then collapsed to create regional estimates. (A list of GBD 22 
2015 Geographies detailing the countries that make up “Regions” and “Super Regions” is 23 
available here: 24 
http://www.healthdata.org/sites/default/files/files/Projects/GBD/GBDRegions_countries.pdf) 25 
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To create a scenario in which risk factors continue the trend observed since 1990 1 
(“business as usual”), the analysis first estimated the proportion of CVD and stroke deaths in 2 
1990 and 2013 due to raised systolic BP, tobacco smoking, high body mass index (BMI) and 3 
high fasting plasma glucose, using a population attributable fraction. The effect of serum 4 
cholesterol was not included because this was not listed among the 8 primary WHO 25 x 25 5 
targets.  6 
   The theoretical minimum risk exposure distribution used for the GDB 2010 study was 7 
applied except for systolic BP where a theoretical minimum limit of 115 mm Hg was adopted.[9] 8 
Using the annualized rate of change between 1990 and 2013, it was assumed that the 9 
remaining deaths unattributed to these risk factors would continue their observed trend.   10 
Beginning in 2014, deaths attributable to the selected risk factors were estimated using the 11 
same population attributable fraction and risk factor exposures estimated for GBD 2013 for each 12 
age-sex-country-year projected to 2025 and the annualized rate of change between 1990 and 13 
2013. Future scenarios were developed to match four key risk factor targets for 2025: 1) no 14 
further rise in fasting plasma glucose, 2) no further rise in BMI, 3) 25% reduction in the 15 
prevalence of systolic BP >140 mm Hg via a shift in the entire population distribution of systolic 16 
BP, and 4) 30% reduction in tobacco smoking prevalence, including associated effects from 17 
second-hand smoke. For blood pressure, modeling a population-wide shift in systolic BP 18 
assumes that there will be both prevention and treatment of hypertension but no blood pressure 19 
target is specified. The analysis also estimated a scenario in which all four of these targets are 20 
achieved, adjusting for their joint effects on mortality. The impact of access to medications was 21 
not modelled because comprehensive estimates do not yet exist. 22 
 23 
Results   24 
2025 Estimates of the Absolute Number of Premature Deaths from CVD 25 
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Using the GBD dataset, 3 736 540 deaths (95% uncertainty interval 3 483 303, 4 009 003) 1 
from CVD occurred in 2013 among men and 2 128 134 (95% uncertainty interval 1 814 857, 2 366 2 
726) among women across the globe for those age 30 to 70 years.  Table 2 shows that, globally, 3 
more men die prematurely from CVD than women, though no significant difference can be observed 4 
in sub-Saharan Africa. For 2025 given population growth and assuming trends in the selected risk 5 
factors continue, we estimate 5 009 492 premature deaths from CVD among men (95% UI (4 632 6 
942,5 389 257)) and 2 769 945 among women (95% UI (2 321 954,3 044 866)) will occur, a relative 7 
increase of 34% and 30% from 2013, respectively.  Only among high-income countries, which 8 
include the United States, Canada, Australia, Western Europe, Japan, and South Korea, are there 9 
projected reductions in the absolute number of premature deaths of -19% among men and -16% 10 
among women in 2025.  For the rest of world, the number of premature deaths from CVD are 11 
projected to increase from 22% in Latin America and the Caribbean to 48% in Sub-Saharan Africa 12 
among women, and from 16% in Central Europe, Eastern Europe, and Central Asia to 56% in 13 
South Asia among men, largely because of aging and growth of populations.   14 
Compared to the “business as usual” estimates, the modelling showed major reductions 15 
in the number of premature deaths from CVD among men and women across all regions if the 16 
25 x 25 targets for raised BP, smoking, obesity and DM were achieved by 2025.  Overall, the 17 
model projected a relative decrease of 5% among men and only a 1% increase among women 18 
in the number of premature deaths from CVD in comparison to the increases of 34% and 30% in 19 
the business as usual estimates.  A significant difference between scenarios in number of 20 
premature deaths due to CVD in 2025, with no overlap of 95% uncertainty intervals, was seen 21 
globally for men and also within the region comprised of Southeast Asia, East Asia, and 22 
Oceania. Although there are projected increases from 2013 to 2025 in the absolute number of 23 
premature deaths in some regions, the 2025 estimates for the number of deaths in all regions 24 
were much improved if the risk factor targets were achieved.  25 
Sacco - 7 
 
 1 
2025 Estimates of Probability of Premature Mortality from CVD 2 
The figures illustrate the global and regional projections for achieving a reduction in the 3 
probability of premature mortality from CVDs, including stroke by 2025. Figure 1 shows the 4 
global probability of premature death in women ages 30 to 70 years due to CVD using data from 5 
1990 to 2013 and projects these estimates from 2014 to 2025.  Notably, recent declines in 6 
premature CVD mortality leveled off if risk factors continue the current trend.  There was a small 7 
estimated reduction in premature mortality if the rise in fasting plasma glucose was halted. A 8 
similar magnitude of decline was estimated if the prevalence of smoking was reduced by 30%.  9 
Next, a more modest reduction in premature mortality would be realized by halting the rise in 10 
elevated BMI.  The most robust effect from a single risk factor target being met resulted from the 11 
achievement of the BP goal of reducing the prevalence of elevated systolic BP by 25%.  An 12 
important assumption of this model is that the entire population distribution of 25% was shifted 13 
leftward to achieve the target, which includes reduction of SBP both greater and less than 140 14 
mmHg. Shifts of this magnitude reflect an assumption that hypertension is both prevented, via 15 
dietary and lifestyle modification, and treated medically, via antihypertensive therapies. However 16 
two key observations of the modelling exercise are that 1) the single dominant risk factor 17 
strategy varied by region and 2) the combined strategy dominated in almost all regions. The 18 
combined scenario if all 4 risk factor targets were achieved by 2025 would result in achieving 19 
the 25x25 mortality goal for women in 2025 or shortly thereafter. 20 
For men, the projections for the global probability of premature death due to CVD 21 
differed (Figure 2).  First, the risk of premature death from CVD was greater for men than 22 
women, and the scenario in which current trends continue to 2025 was estimated to lead to an 23 
increased premature probability of death in 2025 compared to 2013.  If either the rise in fasting 24 
plasma glucose or elevated BMI were halted, then the effects on the premature CVD mortality 25 
among men was less than that for women and no reduction in the risk of premature CVD 26 
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mortality by 2025 could be detected as uncertainty estimates for 2013 and 2025 overlapped.  1 
Achieving the target for smoking would have a similar impact among men and women, reducing 2 
the risk of premature mortality by approximately 4%.  As among women, the BP goal also had 3 
the most profound impact on reducing premature mortality from CVD. The scenario if all 4 risk 4 
factor targets were achieved in 2025 resulted in achieving the overall goal by around 2025 for 5 
both men and women. 6 
 The regional variation in the probability rates for premature CVD mortality was striking, 7 
and the effects of achieving the targets are demonstrated in the figures.  For high income 8 
countries among men and women (Figures 3 and 4), the 2025 premature CVD mortality target 9 
was achieved if current trends continue, but would be achieved about 5 years sooner if all 4 risk 10 
factors targets were achieved.  Higher premature CVD mortality rates were estimated in Eastern 11 
Europe/Central Asia (Figure 5 and 6), Sub−Saharan Africa (Figure 7 and 8), North Africa/Middle 12 
East (Figure 9 and 10), South Asia (Figure 11 and 12), East Asia/Pacific (Figure 13 and 14), 13 
and Latin America/Caribbean (Figure 15 and 16) if current trends continue.  Achieving the 4 risk 14 
factor goals by 2025, however, resulted in the overall 25 x 25 target being achieved on average 15 
in high-income regions, North Africa/Middle East, East Asia/Pacific, Latin America/Caribbean for 16 
men and women.  There is substantial measurement uncertainty for these estimates, 17 
particularly in South Asia.  18 
 19 
Discussion  20 
The data illustrate the substantial variability in the global burden of premature mortality 21 
from CVD with much greater probability of cardiovascular death in low- and middle-income 22 
countries than in high- income countries.  Given that raised systolic BP, smoking, overweight 23 
and obesity, and diabetes are highly prevalent in many populations and increase risk of CVD 24 
death, [10], achieving all 4 of these risk factor targets will contribute to reduction in the risk of 25 
premature mortality from CVD around the year 2025 globally. A key finding of our exercise is 26 
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that, globally and for almost regions, targeting all four of these risk factors leads to greater 1 
reductions in CVD death than targeting any single risk factor. However the absolute impact of 2 
the WHO 25 x 25 priority targets both in combination and independently differ significantly by 3 
world region. 4 
Globally, the targets for systolic BP (reduce by 25%) and tobacco (reduce by 30%) have 5 
more substantial effects on the future scenarios compared with maintaining current levels of 6 
BMI and fasting plasma glucose.  However this general observation is not true for all regions, 7 
notably high-income North America and Australasia where reductions in BMI among women 8 
dominates as a strategy. .[8]. Tobacco reduction is the largest contributor to mortality reductions 9 
for women in Western Europe and high-income Asia Pacific and men in North Africa/Middle 10 
East, Central Sub-Saharan Africa, and Central Asia.[8] Because there is substantial regional 11 
variability in these projections, regions and countries will need to develop, prioritize, implement, 12 
and evaluate context-specific approaches to addressing these targets.  Projections of future 13 
trends can be helpful for setting priorities in certain regions. Although the order of importance of 14 
reaching the individual risk factors varies somewhat by region, the uncertainty intervals largely 15 
overlap and the best scenario for reaching the 25 by 25 goal is to accomplish all 4 key risk 16 
factor targets. 17 
Although the analyses focused on the 4 main risk factor targets, attention needs to be 18 
called to the other targets that involve improving the capacities of healthcare systems to 19 
accomplish CVD risk reduction. Two of the WHO targets that could not be modelled, include (1) 20 
50% of eligible persons receiving drug therapy and counseling including glycemic control to 21 
prevent heart attacks and strokes, and (2) 80% availability of the affordable basic technologies 22 
and essential medicines, including generics, required to treat major NCDs in both public and 23 
private facilities.  It is also important to recognize in interpreting the projections that many of the 24 
8 WHO global targets are inter-dependent.  For example, to achieve the 2025 WHO targets for 25 
BP and DM, major efforts to strengthen healthcare systems will be required.  26 
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 1 
Policy Implications  2 
There are several policy implications of these findings. First, these results demonstrate that 3 
the greatest reduction in premature mortality can be achieved for most regions of the world by 4 
targeting a combination of risk factors. Second, more ambitious risk factor targets will be 5 
needed for fasting plasma glucose and BMI if they are to make a substantial contribution to risk 6 
reduction. A more ambitious tobacco target would also influence non-cardiovascular related 7 
deaths, such as those secondary to cancer and chronic lung disease, which were not included 8 
here. 9 
In order to reduce BP, all three pillars of the global strategy for the prevention and control of 10 
NCDs will be important to address: surveillance, prevention, and health care delivered through 11 
strengthened health systems. These recommendations are described in detail in prevention 12 
guidelines produced by multiple organizations [10-15], and the WHO in its Package of Essential 13 
Non-Communicable Disease Interventions for Primary Health Care.[11] Prevention strategies 14 
and goals for reducing population mean levels of blood pressure, including the including the 15 
WHO target of a 30% relative reduction in mean population intake of salt/sodium intake, are an 16 
important component that can be provided largely by population wide interventions and policies 17 
aimed to improve healthfulness, availability, and affordability of the local and regional food 18 
supply.  19 
Third, projections of future mortality based on the best available data on risk factor exposure 20 
and relative risk can serve as a useful summary measure when WHO Member States and other 21 
stakeholders are setting priorities. To achieve the 25 x 25 mortality goal (Table 3), policy 22 
decisions will need to reflect not only the cost-effectiveness of an intervention targeting a 23 
particular risk factor, but local trends in the absolute level of exposure to that risk factor. 24 
Additional investments in health surveillance will therefore be an essential component of 25 
evidence-based decision-making.[12, 13]  26 
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 1 
Evidence-based prevention and treatment of CVD in low/middle income countries  2 
 Although the model was unable to incorporate the impact of healthcare system changes 3 
in primary and secondary prevention, improving access to evidence-based approaches to the 4 
management of risk to prevent and treat CVDs will be critical to achieving the 2025 goal.  Risk-5 
based management for identification and treatment of individuals at high-risk for CVD and 6 
stroke events has been outlined by the WHO in its Package of Essential Interventions for NCDs 7 
(PEN) in low resource settings. Strategies include non-lab based CVD risk assessment, 8 
simplified treatment protocols based on drugs listed on the WHO Model List of Essential 9 
Medicines, regular audits of the adequacy of human resources, availability of equipment and 10 
laboratory reagents, adherence to clinical protocols, and maintenance of stock registers. 11 
Performance assessments show that implementation of the total-risk approach in primary health 12 
care can lead to significant improvement in blood pressure and diabetes control and to 13 
reductions in cardiovascular risk. In collaboration with ministries of health, the WHO has initiated 14 
similar projects in primary care in approximately 30 resource-constrained settings.[13] 15 
 16 
Strengths and Limitations 17 
The data and results from the GDB2013 study that were used provide, to date, the most 18 
robust estimates of the global and regional burden of cause-specific mortality and risk factor 19 
prevalence.  Mortality data from 1990 through 2013, as well as modeled estimates of risk factor 20 
exposure, were used to create these projections. However, this analysis has limitations.  21 
First, the regional figures appear to have an inflection point present at 2014. The 22 
prediction of future mortality begins in the year 2014 because mortality data was only available 23 
through 2013 at the time of the analysis. In our time series figures, we have elected to show 24 
both estimates of mortality from 1990-2013 as well as the results of our model. This inflection 25 
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point reflects the fact that, for the purpose of comparison, we are showing results of the 1 
GBD2013 study (in black) and result of our projection model (in colors) within the same figure.  2 
Second, the projections reflect counterfactual scenarios based on the theoretical 3 
minimum risk assumed for each risk factor rather than the effect of specific interventions. 4 
Therefore these estimates reflect the combined impact of prevention and treatment, rather than 5 
being limited to treatment of individuals already at elevated risk. This assumption reflects the 6 
fact that both prevention and medical care will play an essential part in reducing the burden of 7 
CVD. 8 
Third, we created models for risk factor targets a) that were limited to those agreed upon 9 
by United Nations Member States in 2013 and b) for which there was sufficient global data on 10 
exposure levels. Fourth, we restricted these analyses to reductions in premature CVD and 11 
stroke deaths. Other NCD goals, including reductions in cancer, DM, and respiratory diseases, 12 
were not estimated, but are also essential to achieving the overall NCD goal.  Fifth, while joint 13 
effects were accounted for in the scenario in which all targets are met, for the BMI scenario only 14 
the direct effect of BMI was estimated on mortality, separate from its effects through BP and 15 
fasting plasma glucose. The inclusion of all the downstream effects of high BMI would have 16 
shown this strategy to have an even larger impact. Because of this decision however, the 17 
combined risk factor scenario was able to correctly account for the joint effects of the selected 18 
risk factors without overestimating the benefit of intervening on multiple metabolic risk factors.  19 
 20 
Conclusions 21 
 By 2025, over 5 million premature deaths from CVD among men and 2.8 million among 22 
women are projected worldwide.  Estimates of the number of people with premature death from 23 
CVD and the probability of dying in 2025 vary across the globe. These data demonstrate wide 24 
variation in estimated future trends in risk factor prevalence and premature CVD mortality that 25 
will require region-and country-specific priority setting to achieve the 25 x 25 goal.  Cost-26 
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effective population wide intervention strategies exist to reduce BP, tobacco, obesity, and DM 1 
but have not been widely implemented.  Aggressive strategies to achieve multiple WHO targets, 2 
especially for raised blood pressure and tobacco control, will be required to meet the 25 x 25 3 
overall goal. Success is possible if the individual WHO targets are met and healthcare systems 4 
are strengthened.  Achieving these goals can only be accomplished if countries and regions set 5 
priorities, implement cost-effective population wide strategies, and collaborate in public-private 6 
partnerships across multiple sectors.  7 
 8 
 9 
 10 
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TABLE 1. Trends in Global Cardiovascular Health  1 
 Global Prevalence 
 1980 2008-2012 
Metric Men Women Men Women 
Tobacco use, %[14] 
41.2  
(40.0, 42.6) 
10.6  
(10.2, 11.1) 
31.1  
(30.2, 32.0) 
6.2  
(6.0, 6.4) 
Mean SBP, mmHg[15] 
130.5  
(127.3, 134.0) 
127.2  
(124.1, 130.6) 
128.1  
(126.7, 129.4) 
124.4  
(123.0, 125.9) 
Raised Blood Pressure, 
% [15] 
33 
(28, 39) 
29 
(25, 34) 
29 
(27, 31) 
25 
(23,27) 
Phys. inactivity, %[16] N/A N/A 
19.8 
(13.4-32.1) 
26.8 
(18.5-38.9) 
Obesity, %[17] 
4.8  
(4.0, 5.7) 
7.9 
(6.8, 9.3) 
9.8  
(9.2, 10.4) 
13.8  
(13.1, 14.7) 
Diabetes, % [18] 
8.3  
(6.5, 10.4) 
7.5  
(5.8, 9.6) 
9.8  
(8.6, 11.2) 
9.2  
(8.0, 10.5) 
 2 
 3 
  4 
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TABLE 2. Absolute Numbers of Premature Cardiovascular Deaths in 2013 and Estimates in 2025 for Adults age 30 to 70 1 
years by Super- Region 2 
Region Sex 
Premature 
Cardiovascular 
Deaths, 2013 (95% 
uncertainty interval) 
Premature 
Cardiovascular 
Deaths in 2025 if 
Current Risk Factor 
Trends Continue (95% 
uncertainty interval) 
Percentage 
Change in Mean 
Number of 
Deaths, 2013-
2025 
Premature 
Cardiovascular 
Deaths in 2025 if 
Risk Factor Targets 
are Achieved (95% 
uncertainty interval) 
Percentage 
Change in 
Mean Number 
of Deaths, 
2013-2025 
Global Women 
2128134 
(1814857,2366726) 
2769945 
(2321954,3044866) 30% 
2159217 
(1827170,2393080) 1%  
Global Men 
3736540 
(3483303,4009003) 
5009492 
(4632942,5389257) 34%* 
3539896 
(3316386,3804971) -5% ⱡ  
High-income Women 
164786 
(148636,205642) 
138356 
(124811,172797) -16% 
127186 
(114450,158685) -23% 
High-income Men 
362839 
(342716,383975) 
293289 
(276513,311016) -19%* 
266359 
(250676,283268) -27%* 
Central Europe, 
Eastern Europe, and Women 
223696 
(207857,243869) 
281455 
(245400,302032) 26%* 
227418 
(195576,246731) 2% 
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Central Asia 
Central Europe, 
Eastern Europe, and 
Central Asia Men 
475936 
(461227,490469) 
553462 
(531778,574519) 16%* 
410376 
(389566,430121) -14%* ⱡ  
Sub-Saharan Africa Women 
200443 
(177291,240632) 
296141 
(257813,347694) 48%* 
237249 
(207346,282389) 18%  
Sub-Saharan Africa Men 
231248 
(216576,247674) 
350375 
(327371,374645) 52%* 
289286 
(269767,311035) 25%* ⱡ  
North Africa and 
Middle East Women 
147122 
(130915,163220) 
194795 
(173397,217242) 32%* 
168165 
(149818,187378) 14% 
North Africa and 
Middle East Men 
220032 
(204031,238444) 
295956 
(274405,319530) 35%* 
247057 
(228401,267836) 12% ⱡ  
South Asia Women 
639046 
(469768,794972) 
916908 
(665308,1130215) 43% 
736819 
(532380,910343) 15%  
South Asia Men 
1097544 
(904270,1317289) 
1717276 
(1418260,2039056) 56%* 
1223642 
(1020301,1457277) 11% ⱡ  
Southeast Asia, East Women 626804 788050 26% 535645 -15% ⱡ  
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Asia, and Oceania (537293,720433) (672937,899995) (461842,609289) 
Southeast Asia, East 
Asia, and Oceania Men 
1163003 
(1017097,1282170) 
1568704 
(1373123,1748215) 35%* 
912417 
(814746,1000303) -22%* ⱡ  
Latin America and 
Caribbean Women 
126235 
(115538,147773) 
154240 
(140363,179209) 22% 
126736 
(115135,147858) 0% 
Latin America and 
Caribbean Men 
185937 
(175438,196925) 
230430 
(217845,242639) 24%* 
190760 
(180293,201545) 3% ⱡ  
* Indicates that 95% uncertainty interval for number of deaths in 2013 and 2025 do not overlap; ⱡ indicates that 95% uncertainty 1 
interval for numbers of deaths in 2025 scenarios do not overlap 2 
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TABLE 3. Cost Effective Population Level Strategies to Achieve Targets   1 
WHO Risk Factor 
Targets and 25 x 25 Goals 
Strategies for Population Wide Intervention 
Tobacco  
A 30% relative reduction in 
prevalence of current tobacco 
use in persons aged 15+ 
years 
 Higher taxes on tobacco products to reduce use and fund tobacco 
control programs[12, 19]  
 Smoke-free indoor workplaces, public places and public transport  
[12, 19, 20] 
 Mass media campaigns about the danger of tobacco and tobacco 
smoke including cigarette package warnings, especially those that 
are graphic and health related [12, 19] 
 Complete bans on all forms advertising, promotion and sponsorship 
of tobacco products [12, 19]  
High Blood Pressure & 
Sodium Reduction 
 
A 25% relative reduction in 
the prevalence of raised 
blood pressure or contain the 
prevalence of raised blood 
pressure, according to 
national circumstances  
 
A 30% relative reduction in 
mean population intake of 
salt/sodium intake 
 Enact government policies to reduce sodium in packaged foods. [21, 
22]  
 Mass-media campaigns and voluntary action by food industry to 
reduce sodium consumption. [23] 
 Implement public awareness programs on diet and physical activity 
[24] 
 Drug therapy (including glycemic control for diabetes mellitus and 
control of raised blood pressure using a total risk approach) and 
counselling to individuals who have had a heart attack or stroke and 
to persons with high risk (≥ 30%) of a fatal and nonfatal 
cardiovascular event in the next 10 years [24] 
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Unhealthy Diet & 
Physical Inactivity 
 
Halt the rise in diabetes and 
obesity 
 
A 10% relative reduction in 
prevalence of insufficient 
physical activity 
 
 
 Replace trans fats with unsaturated fats [24] 
 Implement public awareness programs on diet and physical activity 
[24] 
 Fiscal methods that increase the price of foods high in saturated and 
industrially produced trans fats and sugar; food labelling; and 
marketing restrictions of unhealthy food products, especially to 
children and young people.[25] 
 Restrict advertising to children [24] 
 Drug therapy (including glycemic control for diabetes mellitus and 
control of raised blood pressure using a total risk approach) and 
counselling to individuals who have had a heart attack or stroke and 
to persons with high risk (≥ 30%) of a fatal and nonfatal 
cardiovascular event in the next 10 years [24] 
 
Population wide interventions must be considered to impact progress towards the modifiable 1 
risk factor targets.  2 
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